Comparative Analysis of Efficacy of Oxaceprol Versus Tramadol for Knee Osteoarthritis: An Institutional Based Study
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 5, Pages 616-619
AbstractBackground: The most common form of arthritis with approximately 250 million people worldwide conservatively estimated to be suffering from osteoarthritis of the knee alone. The present study was conducted to compare Oxaceprol and tramadol for knee osteoarthritis.
Material and methods: This prospective, comparative study was carried among patients diagnosed as Osteoarthritis. A total of 200 patients randomized in two study groups of 100 patients each. Each group was given either oxaceprol 200 mg capsule or tramadol 50 mg capsule, thrice daily after food, for 12 weeks. The primary efficacy variable for this study was symptom relief and was assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The data have subjected to Paired and Independent t-test as applicable. P values less than 0.05 were considered as significant.
Results: In the present study a total of 200 patients randomized in two study groups of 100 patients each were included in the study. Each group was given either oxaceprol 200 mg capsule or tramadol 50 mg capsule. In tramadol group 45% were males and 55% were females and mean age of participants was 51.37yrs whereas in Oxaceprol group 48% were males and 52% were females and mean age of participants was 50.42 yrs. No statistically significant difference was observed between groups for WOMAC scores. Significant reduction in pain, stiffness and physical function was observed between oxaceprol and tramadol group at baseline and after 6 months follow-up.
Conclusion: The present study concluded that Oxaceprol efficacy and tolerability was comparable with tramadol and the drug can be considered as an alternative to low-potency opioids in the management of knee osteoarthritis.
- Article View: 4
- PDF Download: 6